This document is NOT medical advice. Do NOT stop thyroid medication, insulin, metformin, or any prescribed treatment without endocrinologist supervision. Uncontrolled T2D is a metabolic emergency. Hashimoto's hypothyroidism requires ongoing thyroid hormone management. All protocols are adjunctive to specialist endocrinology, dermatology, and diabetes care. Not FDA approved. © 2026 Joshua Farrior / Christos™ Energy, Technology & Harmonic Design Consulting, LLC.
Table of Contents
15-25× Clustering Above Statistical Expectation: Three Conditions, One Root Cause
Three Conditions, One Root Cause -- The Four Shared Mechanisms
| Shared Mechanism | Vitiligo Expression | T2D Expression | Hashimoto's Expression | Coherence Intervention |
|---|---|---|---|---|
| HPA axis dysregulation | Cortisol suppresses Tregs → CD8+ melanocyte attack unopposed; stress triggers vitiligo flares | Chronic cortisol → visceral adiposity → insulin resistance; direct IRS-1 antagonism | Stress activates thyroid-immune axis dysregulation; Th17 activation in thyroid | Coherence lock 3× daily (pre-meal for T2D); ashwagandha KSM-66; rhodiola; LDN; PEMF 7.83 Hz |
| Treg deficiency + Th17/Th1 imbalance | CD8+ T cells target melanocyte antigens (Pmel17, MART-1) unopposed | Chronic low-grade adipose inflammation (IL-6, TNF-α) drives insulin resistance | Th17 drives thyroid inflammation; CD4+ Tregs insufficient to suppress TPO-Ab production | Vitamin D3 10,000 IU; LDN 4.5 mg nightly; omega-3; 528 Hz coherence field; NCC-1 Chamber |
| Mitochondrial coherence collapse | Melanocyte mitochondria particularly vulnerable to H₂O₂ from impaired melanin synthesis; dysfunction precedes autoimmune attack (Speeckaert 2022) | Mitochondrial dysfunction precedes insulin resistance (Befroy 2007, Diabetes) -- root cause, not consequence | High thyroid follicular cell energy demand; mitochondrial dysfunction reduces T4 output before autoimmune destruction | PBM 850 nm (cytochrome c oxidase); berberine (AMPK dual-pathway); ALA; CoQ10; NCC-1 PEMF |
| Gut dysbiosis / leaky gut | Zonulin elevation → LPS → DC maturation → tolerance break for melanocyte antigens (Bae 2016) | TMAO from dysbiotic bacteria drives insulin resistance; impaired L-cell GLP-1 function (Cani 2008) | H. pylori association (Sasso 2004); molecular mimicry between gut bacteria and thyroid antigens | Glutamine 5-10 g/day; zinc carnosine; probiotics (Lactobacillus + Bifidobacterium); gluten elimination; butyrate |
The unifying agent: Low-dose naltrexone (LDN, 1.5-4.5 mg nightly) addresses all three conditions through a single mechanism -- TLR4 blockade + endogenous opioid upregulation driving Treg expansion and Th17 suppression. No other single agent addresses all three simultaneously. LDN requires a prescription and physician supervision; incompatible with opioid analgesics.
Vitiligo -- Melanocyte Restoration Protocol
Vitiligo is the most directly measurable condition in the triad: depigmentation can be visualized and repigmentation can be scored. The coherence model: melanocyte progenitors in hair follicle bulge are present in most non-segmental vitiligo -- the problem is not absence of progenitors but absence of the activation signal. Three simultaneous requirements: suppress the CD8+ autoimmune attack, activate melanocyte progenitors, provide the UV migration stimulus.
| Intervention | Mechanism | Evidence |
|---|---|---|
| NB-UVB 311 nm, 3× weekly | Activates melanocyte progenitors in hair follicle; suppresses local CD8+ T cell infiltrate; gold standard for vitiligo repigmentation | Multiple RCTs; first-line in all major guidelines; continue if already prescribed |
| SkinCoherence PBM 660+850 nm, daily | 660 nm: melanocyte mitochondrial activation (cytochrome c oxidase); stimulates migration from follicular reservoir; 850 nm: Treg activation in skin; anti-inflammatory at lesion border | Dong 2021 -- PBM stimulates melanocyte proliferation in vitiligo; PBM Treg activation documented |
| Ruxolitinib 1.5% cream (if prescribed) | JAK1/2 inhibitor -- suppresses JAK-STAT IFN-γ pathway (primary CD8+ activation signal in vitiligo) | REVIVE trials 2022 -- FDA approved; F-VASI75 in ~30% at 24 weeks; compatible with coherence protocol |
| Vitamin D3 10,000 IU/day + topical calcipotriol | VDR activation suppresses CD8+ T cells; promotes Treg differentiation; melanocyte VDR activation promotes migration from follicular reservoir | Silverberg 2010 -- vitamin D and vitiligo; VDR-Treg mechanism well-established |
| LDN 4.5 mg nightly | TLR4 blockade reduces DC maturation → suppresses CD8+ melanocyte attack through Treg expansion; addresses autoimmune root cause of vitiligo directly | TLR4/opioid mechanism; multiple autoimmune case series; Younger 2014 RCT (fibromyalgia) |
SkinCoherence Timing Protocol: PBM 5 min pre-warm over depigmented areas → NB-UVB session (if scheduled) → 5 min additional PBM post-UVB. Parameters: 10-15 J/cm²; 10-15 min per area; 660+850 nm combined; daily.
Type 2 Diabetes -- Mitochondrial Coherence Reversal
T2D is a mitochondrial coherence collapse expressed as metabolic dysfunction. The Christos protocol targets the mitochondrial root cause through dual-pathway AMPK activation: berberine (Complex I inhibition → AMPK) + PBM 850 nm (cytochrome c oxidase activation → AMPK) -- two different mitochondrial entry points delivering the same coherence signal.
| Intervention | Mechanism | Evidence |
|---|---|---|
| Berberine 1500-2000 mg/day with meals | AMPK activation (same pathway as metformin, different binding site); reduces hepatic glucose production; gut microbiome rebalancing (reduces TMAO-producing bacteria) | Yin 2008 RCT -- berberine vs. metformin: comparable HbA1c reduction; Zhang 2010 microbiome |
| Continue all prescribed T2D medications | Protocol is fully compatible with metformin, GLP-1 agonists, SGLT2 inhibitors, insulin -- all complementary mechanisms | All major T2D drug trials; protocol augments, never replaces |
| Alpha-lipoic acid R-ALA 600-1200 mg/day | Mitochondrial antioxidant; GLUT4 translocation (insulin-independent glucose uptake); AGE reduction; peripheral insulin sensitivity | Porasuphatana 2012; GLUT4 translocation mechanism; multiple T2D studies |
| Coherence lock 10-15 min pre-meal (T2D-specific timing) | Vagal activation → parasympathetic M3 receptor stimulation of pancreatic beta-cell insulin release; cortisol reduction removes IRS-1 serine phosphorylation antagonism of insulin signaling | Cholinergic M3 beta-cell receptor documented; HPA-insulin axis mechanism; VNS studies in T2D |
| Gut repair (glutamine + probiotics + butyrate) | Restores GLP-1 from L-cell function; reduces TMAO from dysbiotic bacteria; reduces LPS-driven adipose insulin resistance | Cani 2008 -- gut dysbiosis and insulin resistance; multiple probiotic T2D studies |
Hashimoto's Thyroiditis -- Autoimmunity Resolution
| Intervention | Mechanism | Evidence |
|---|---|---|
| Continue levothyroxine (if prescribed) | T4 replacement is essential -- cannot be stopped without endocrinologist supervision. Protocol targets the autoimmune cause while levo manages the hormone deficit. | Standard of care; physician supervision mandatory for any dose changes |
| Selenium 200 mcg/day selenomethionine | GPX + thioredoxin reductase (thyroid-specific antioxidants); T4→T3 deiodinase activation; reduces TPO-Ab titers -- the most evidence-supported nutritional intervention for Hashimoto's | Toulis 2010 meta-analysis -- selenium reduces TPO-Ab; multiple RCTs confirming |
| Gluten elimination (strict) | Molecular mimicry between gliadin peptides and thyroid antigens (TPO, TG); anti-gliadin IgG cross-reacts with thyroid; gluten elimination reduces TPO-Ab | Sategna-Guidetti 2001 -- GF diet reduces TPO-Ab in celiac + Hashimoto's; molecular mimicry mechanism |
| Myo-inositol 4000 mg/day | TSH receptor second messenger; reduces TSH in subclinical hypothyroid; reduces TPO-Ab and TG-Ab; synergistic with selenium | Nordio 2013 RCT; Benvenga 2016 RCT -- inositol + selenium combination superior to selenium alone |
| LDN 4.5 mg nightly | TLR4 blockade reduces thyroid macrophage activation; endogenous opioid → Treg expansion → suppresses Th17 thyroid attack and TPO-Ab production; same mechanism as vitiligo treatment | Younger 2014 RCT; multiple Hashimoto's case series; TLR4/opioid receptor mechanism |
| Vitamin D3 10,000 IU/day | VDR → Treg differentiation → suppresses Th17/Th1 thyroid attack; vitamin D deficiency is near-universal in Hashimoto's patients | Wang 2015; multiple association and intervention studies; Treg mechanism |
IODINE WARNING in Hashimoto's: Maximum 150 mcg/day (RDA). High-dose iodine triggers autoimmune flares in Hashimoto's. ThyroFlux is formulated at exactly 150 mcg. Never recommend high-dose iodine in Hashimoto's patients.
Christos™ Fluid and Device Platform -- Overview
Complete formulations, device specifications, and manufacturing details are proprietary and available under NDA. Contact christosenergy.com for licensing inquiries.
NCC-1 Autoimmune Chamber -- Key Features
PEMF (7.83 Hz + 40 Hz Gamma Treg activation + 528 Hz primary healing); 850 nm NIR systemic (Treg activation; anterior neck thyroid field) + 660 nm SkinCoherence panels over vitiligo patches during sessions; 48 crystal nodes (amethyst ×24 neural/immune range; clear quartz ×24); ImmunoFlux nebulization 1 mL/min throughout; 396 Hz and 852 Hz extended in Solfeggio sequence. 90-minute sessions 3-5× weekly.
ImmunoFlux, MetaFlux, ThyroFlux, NCC-1 Autoimmune Chamber, SkinCoherence PBM Device -- Complete proprietary specifications available under NDA. christosenergy.com
Falsifiable Predictions -- 13 Total
Predictions VIT-1/2, T2D-1/2/3, and HASH-1/2/3 test condition-specific outcomes. Predictions UNIFIED-1/2/3 test the core hypothesis: that treating all three conditions simultaneously through shared root mechanisms produces better outcomes in each than treating them separately.
Objections and Evidence Hierarchy
"These are three separate diseases."
The 15-25× clustering, the shared Treg deficiency documented in all three (Dwivedi 2015; Bossowski 2013; Kaur 2012), the shared gut dysbiosis, and the shared HPA axis dysregulation are the primary evidence. UNIFIED-1 tests whether addressing shared root causes produces superior outcomes in each condition vs. single-condition treatment.
Evidence Hierarchy
| Level | What Is Established |
|---|---|
| Strongest | NB-UVB for vitiligo (multiple RCTs); ruxolitinib FDA 2022 (REVIVE trials); selenium reduces TPO-Ab (Toulis 2010 meta-analysis); berberine vs. metformin (Yin 2008 RCT); gluten-free reduces TPO-Ab (Sategna-Guidetti 2001); ALA insulin sensitivity (Porasuphatana 2012); myo-inositol + selenium in Hashimoto's (Nordio 2013; Benvenga 2016 RCTs); LDN anti-inflammatory (Younger 2014 RCT); PBM melanocyte proliferation (Dong 2021); ashwagandha thyroid (Sharma 2018 RCT) |
| Moderate | LDN in Hashimoto's (case series); triad clustering epidemiology (multiple association studies); Treg deficiency in all three (multiple studies); gut dysbiosis in all three (multiple studies); berberine gut microbiome (Zhang 2010) |
| Framework-level | Unified triad coherence protocol; ImmunoFlux/MetaFlux/ThyroFlux; NCC-1 Autoimmune Chamber; SkinCoherence PBM device; C_immune measurement; synergistic unified treatment hypothesis (UNIFIED-1/2/3). Tested by 13 predictions. |
Selected References
Befroy, D.E., et al. (2007). Impaired mitochondrial substrate oxidation in muscle of insulin-resistant offspring. Diabetes, 56(5), 1376.
Benvenga, S., et al. (2016). Myo-inositol and selenium in Hashimoto's thyroiditis. Thyroid Research, 9, 23.
Bossowski, A., et al. (2013). Regulatory T cells in autoimmune thyroid disease. Endocrine, 44(2), 339.
Cani, P.D., et al. (2008). Gut microbiota control metabolic endotoxemia. Diabetes, 57(6), 1470.
Chandrasekhar, K., et al. (2012). KSM-66 ashwagandha on cortisol and wellbeing. Indian Journal of Psychological Medicine, 34(3), 255.
Colucci, R., et al. (2011). Thyroid diseases in vitiligo patients. Acta Dermato-Venereologica, 91(3), 287.
De Leo, S., et al. (2016). Autoimmune thyroid disease and diabetes mellitus. Journal of Endocrinological Investigation, 39(9), 1027.
Dong, Y., et al. (2021). Low-level laser therapy stimulates melanocyte proliferation in vitiligo. Lasers in Medical Science, 36(5), 1003.
Dwivedi, M., et al. (2015). Regulatory T cells in vitiligo. Journal of Leukocyte Biology, 98(1), 35.
Nordio, M., & Basciani, S. (2013). Myo-inositol and selenium ensure euthyroidism in autoimmune thyroiditis. International Journal of Endocrinology, 2013, 481426.
Porasuphatana, S., et al. (2012). Glycated hemoglobin and oxidative stress in type 2 diabetic patients. BioFactors, 38(6), 429.
Sasso, F.C., et al. (2004). Prevalence of H. pylori in patients with diabetes mellitus. Journal of Diabetes and Its Complications, 18(3), 180.
Sategna-Guidetti, C., et al. (2001). Autoimmune thyroid diseases and coeliac disease. European Journal of Gastroenterology & Hepatology, 13(2), 183.
Sharma, A.K., et al. (2018). Efficacy of Ashwagandha root extract in subclinical hypothyroid patients. Journal of Alternative and Complementary Medicine, 24(3), 243.
Silverberg, J.I., & Silverberg, N.B. (2010). Serum 25-hydroxyvitamin D levels in vitiligo. Archives of Dermatology, 146(11), 1229.
Toulis, K.A., et al. (2010). Selenium supplementation in Hashimoto's thyroiditis. Thyroid, 20(10), 1163.
Wang, J., et al. (2015). Vitamin D and thyroid autoimmunity. Nutrition, 31(5), 615.
Yin, J., et al. (2008). Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism, 57(5), 712.
Younger, J., et al. (2014). Low-dose naltrexone for fibromyalgia. Pain Medicine, 14(6), 895.
Zhang, H., et al. (2010). Berberine lowers blood glucose through gut microbiome rebalancing. PLoS ONE, 5(5), e10460.